MeTA KYRGYZSTAN - PowerPoint PPT Presentation

1 / 12
About This Presentation
Title:

MeTA KYRGYZSTAN

Description:

MeTA KYRGYZSTAN Medicines Quality Assessment from Retail Market using Mini-Lab Kits * * – PowerPoint PPT presentation

Number of Views:112
Avg rating:3.0/5.0
Slides: 13
Provided by: Inven5
Category:

less

Transcript and Presenter's Notes

Title: MeTA KYRGYZSTAN


1
MeTA KYRGYZSTAN
  • Medicines Quality Assessment from Retail Market
    using Mini-Lab Kits

2
Situational analysis
  • An estimated 30 of medicines are imported
    illegally and most of the population is inclined
    to the self-treatment.
  • No surveys have been conducted at the retail
    level for assuring quality of medicines in the
    Kyrgyz Republic.
  • Despite the efforts undertaken by the National
    DRA the illegal trade of medicines still exists
    in the black market in the country (eg. Osh
    bazar, Dordoy bazar in Bishkek where some people
    seek cheap medicines sources).
  • The National DRA is the only body which has
    mandate to ensures quality of medicines.
  • There is a contradiction in the regulatory
    management between obligations of the DRA on
    ensuring medicines quality and judicial powers.
    For example, DRA inspectors are not permitted to
    carry out unannounced inspections in the
    pharmacies and wholesale drugstores without prior
    10 days notice and given permission of the Public
    Prosecutors Office and Ministry of Economic
    Regulation.

3
How MeTA has addressed quality
  • Two mini-labs were procured (GPHF- minilab)
    within MeTA activities
  • The USP trainers trained 9 people on using
    mini-labs, including lab assistants of the DRA QC
    Lab and a private QC Lab Pharmacia, and a
    teacher of Pharmaceutical Department of the
    Kyrgyz State Medical Academy
  • The medicines samples were gathered in
  • Bishkek (capital) 227 samples (84 143)
  • Karakol town 82
  • Osh city 100
  • Djalalabat town 138
  • Totally 547 samples

4
How MeTA has addressed quality
  • 6 INN were selected
  • 1. Amoxicillin
  • 2. Ciprofloxacin
  • 3. Metronidazole
  • 4. Acetylsalicylic acid
  • 5. Aminophyllin
  • 6. Paracetamol

5
Results of TLC and physical examination
(investigators reports)
  • It should be noted that there are examples of
    drugs that do not match the following criteria
  • - labeling (Acetylsalicylic acid, Amoxicillin) -
    the same manufacturer, but the addresses and
    phone numbers are different, the color of packs
    are the same, but shades are of different
    intensity, sometimes the manufacturer is not
    specified
  • - appearance - samples are contaminated in
    bottles (Aminophyllin), and are not uniform in
    color (blotches of darker shades)
  • - for some samples the TLC-analysis was altered
    up to 3 times (three different tablets), because
    the intensity of emission comparing with the
    standard differed significantly we assumed that
    the samples were not homogeneous in content of
    active substances within the series, (or one
    package), this is mainly about the samples of
    Paracetamol and Acetylsalicylic acid
  • - many samples of acetylsalicylic acid were
    disintegrated in 30-50 seconds already.

6
Results of TLC and physical examination
(investigators reports)
INN No. samples N, Problems with Quality , Quantity (TLC, Rf) No. Problems Labelling No. Expired date No. Suspicious tablets apperance No. Satisfactory samples of satisfactory samples
Amoxicillin 104 6 23 1 4 70 68
Ciprofloxacin 104 26 1 3 1 73 71
Aminophyllin 53 1 0 0 2 50 95
Metronidazole 102 15 3 0 15 69 68
Acetylsalicylic acid 91 9 3 0 0 79 87
Paracetamol 93 7 0 0 3 83 90
Totally 547 64 30 4 25 424 78
7
Survey Findings
8
Successes
  • The results are indicative of need to amend and
    improve current legislation, for example
  • Enhancing authority/power of inspectors/DRA
  • Development of post-marketing surveillance over
    drug quality
  • The country has acquired a new method for testing
    Quality of medicines in the market
  • Additional skills have been acquired by way of
    trained personnel other than DRA staff to apply
    the Mini Labs for testing Quality of Medicines
  • The Pharmacia Department of the Kyrgyz State
    Medical Academy has skills on using mini-labs and
    can train the students
  • Statistical data on the number and location of
    pharmacies inside and near to the Family Medicine
    Centers of Bishkek have been accquired as a
    result of the Survey
  • The samples of illegally sold medicines have been
    gathered (Osh bazar) and are currently in the
    process of testing

9
Challenges
  • There is no separate data on the pharmacies
    located in every administrative district in
    Bishkek (capital city)
  • The addresses of the pharmacies included into a
    DRA Reference Book do not correspond to the
    factual locations
  • Many pharmacies do not have cash registers,
    making it difficult to provide financial
    statements for the purchased samples ?f medicines
  • QC Laboratory/DRA was not convinced of the
    advantages / benefits to use the mini-labs to
    assess the quality of medicines. This led to
    significant delay in getting the test results

10
Lessons learned
  • Post marketing Surveillance is essential for
    assuring Quality of medicines circulating in the
    market
  • Weaknesses in Legislation do not allow the DRA to
    perform its regulatory role efficiently and
    effectively
  • Only 78 of samples collected met the quality
    requirements hence it is evident that quality of
    medicines in the market is unreliable
  • Currently the following questions should be
    solved
  • - who will be using the mini-labs after
    completion of MeTA activity? (quite expensive
    chemicals and USP standards)
  • - who will be getting the samples, how often and
    how many as it is the issue on expenditures
    related to buying samples in the pharmacies
  • - who will be paying expenditures involved into
    full analysis of the questionable quality
    medicines?
  • - coverage? Urban areas, rural areas, regions?

11
RECOMMENDATIONS OR FURTHER ACTIONS TO BE
UNDERTAKEN
  • Strengthen regulatory control of medicines and
    enforcement by national DRA to prevent and detect
    counterfeit/substandard medicines (through
    improvement of current legislation, see above).
  • A range of stakeholders not just health
    professionals is needed. The aim is to involve a
    range of stakeholders in collaborative efforts to
    protect people from buying and taking
    counterfeit/substandard medicines.
  • Make all findings with regards to actions held
    by NDRA publicly available.
  • Regular Public media campaigns to raise public
    awareness on public health risk of the
    self-treatment and buying medicines from
    non-regulated outlets, where the incidence of
    substandard drugs is likely to be higher.

12
Thank you
  • Prepared by Kyrgyz MeTA Secretariat
  • Email kg_meta_council_at_googlegroups.com
  • Phone number 996 (312) 900-411
  • Skype asuluke
  • Website www.metakg.org
Write a Comment
User Comments (0)
About PowerShow.com